Similar articles

• A case of lipoatrophy with insulin glargine: long-acting insulin analogs are not exempt from this complication.

  Ampudia-Blasco FJ, Girbes J, Carmena R. Ampudia-Blasco FJ, et al. Diabetes Care. 2005 Dec;28(12):2983. doi: 10.2337/diacare.28.12.2983. Diabetes Care. 2005. PMID: 16306570 No abstract available.
• Lipoatrophy associated with the use of insulin analogues: a new case associated with the use of insulin glargine and review of the literature.

  Holstein A, Stege H, Kovacs P. Holstein A, et al. Expert Opin Drug Saf. 2010 Mar;9(2):225-31. doi: 10.1517/14740330903496402. Expert Opin Drug Saf. 2010. PMID: 20001763 Review.
• [Lipoatrophic diabetes].

  Danilishina VS, Les'kiv NR. Danilishina VS, et al. Klin Med (Mosk). 1981 Jan;59(1):91-2. Klin Med (Mosk). 1981. PMID: 7241979 Russian. No abstract available.
• [Insulin-induced lipoatrophy in children].

  Niinikoski H, Näntö-Salonen K, Ruusu P, Kinnala A, Putto-Laurila A, Toppari J, Keskinen P. Niinikoski H, et al. Duodecim. 2010;126(11):1328-32. Duodecim. 2010. PMID: 20681357 Finnish.
• Lipoatrophic diabetes: a case report with a brief review of the literature.

  Lawson MA. Lawson MA. J Adolesc Health. 2009 Jan;44(1):94-5. doi: 10.1016/j.jadohealth.2008.06.007. Epub 2008 Sep 27. J Adolesc Health. 2009. PMID: 19101466 Review.